Quality of life

The most common treatment goal defined by symptomatic severe aortic stenosis (ssAS) patients is an improvement in Quality of Life (QoL)¹
TAVI can help your ssAS patients achieve treatment goals that matter the most to them ^1-6
TAVI has demonstrated faster recovery compared to surgery as well as a rapid return to daily activities^{2, 3}

Patients seek QoL improvement as the primary treatment goal¹

93% of patients who underwent TAVI said improved QoL was their primary treatment goal. Patients favoured the ability to enjoy their regular activities and spend time with loved ones over goals relating to heart failure symptomatology: *

Improvements in quality of life with TAVI ¹

Data on primary quality of life goals for 46 high-surgery risk AS patients who chose TAVI over medical treatment or palliative care. The expanded pie chart only represents the 93% who expressed a QoL goal as their primary goal.

TAVI offers patients a rapid return to daily activities²

A return to daily activities is the most frequently reported goal of treatment followed by maintaining or improving independence.¹ TAVI demonstrated a greater improvement of patient-defined goals at 30 days compared with surgery:^2‡

Change in percentage of patients without symptoms or activity limitations at 30 days²

The PARTNER II Trial intermediate-risk cohort unadjusted rates, as-treated population (n=1,818). Showing representative questions of daily life activities from EuroQol-5D (EQ-5D) and short form KCCQ-12. The graph represents select categories, other daily life activities from EQ-5D and KCCQ-12. Activities captured by these quality of life measures include: hobbies or recreational activities, visiting family or friends out of their home, hurrying or jogging (as if to catch a bus) and the frequency of: shortness of breath, sleeping sitting up, and swelling in feet, ankles or legs upon waking. Patients reporting “limited for other reasons or did not do the activity” were not included in the analysis.

TAVI demonstrates early and sustained QoL benefits in all risk groups ^{3, 6}

Data from the PARTNER 3, II S3i, 1A and 1B Trials show that patients receiving TAVI enjoyed a better health status post-procedure compared to control group (sAVR or standard treatment), as measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ).

Low-risk

Intermediate-risk

High-risk

Inoperable

Low-risk

Intermediate-risk

High-risk

Inoperable

Clinical implications

What could a TAVI referral mean for your ssAS patients?

Stay informed with our newsletter

For signing up to the monthly Edwards Lifesciences TAVI newsletter. You will now receive emails on the latest developments and industry insights on aortic stenosis

Terms and conditions

By providing your personal information, you agree to allow Edwards Lifesciences and its agents to use this information to communicate with you in the future, including information about services, events, and programs. Edwards Lifesciences and its agents will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Edwards Lifesciences and its agents, Edwards Lifesciences will use your information in accordance with the Edwards privacy policy.

Our monthly updates provide you the latest developments in TAVI and aortic stenosis. Read more

References

1Coylewright M. et al. Health Expect. 2016;19(5):1036-1043.
2Edwards data on file.
3Baron SJ, et al. J Am Coll Cardiol. 2019;74(23):2833–2842.
4Baron SJ, et al. JACC: Cardiovascular Interventions. 2018;11(12):1188-1198.
5 Reynolds MR, et al. J Am Coll Cardiol 2012;60:548–558.
6Reynolds MR, et al. Circulation. 2011;124:1964-1972.

Quality of life

Patients seek QoL improvement as the primary treatment goal1

Improvements in quality of life with TAVI 1

TAVI offers patients a rapid return to daily activities2

Change in percentage of patients without symptoms or activity limitations at 30 days2

TAVI demonstrates early and sustained QoL benefits in all risk groups 3, 6